These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 14750459)

  • 21. Improving antidepressant adherence.
    Nemeroff CB
    J Clin Psychiatry; 2003; 64 Suppl 18():25-30. PubMed ID: 14700452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Venlafaxine extended-release: a review of its use in the management of major depression.
    Wellington K; Perry CM
    CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antidepressant discontinuation: a review of the literature.
    Lejoyeux M; Adès J
    J Clin Psychiatry; 1997; 58 Suppl 7():11-5; discussion 16. PubMed ID: 9219488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence of early anxiety aggravation in trials of selective serotonin reuptake inhibitors in depression.
    Näslund J; Hieronymus F; Emilsson JF; Lisinski A; Nilsson S; Eriksson E
    Acta Psychiatr Scand; 2017 Oct; 136(4):343-351. PubMed ID: 28859218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paroxetine: a selective serotonin reuptake inhibiting antidepressant.
    Caley CF; Weber SS
    Ann Pharmacother; 1993 Oct; 27(10):1212-22. PubMed ID: 8251692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Venlafaxine versus SSRI therapy for major depression. Results of comparative efficacy trials.
    Bakish D
    Postgrad Med; 1999 Nov; 106(6 Suppl):24-30. PubMed ID: 19667501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Withdrawal syndrome after the use of serotonin reuptake inhibitors].
    Fagan M
    Tidsskr Nor Laegeforen; 2000 Mar; 120(8):913-4. PubMed ID: 10795494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Focus on paroxetine.
    Green B
    Curr Med Res Opin; 2003; 19(1):13-21. PubMed ID: 12661775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Newer generation antidepressants for depressive disorders in children and adolescents.
    Hetrick SE; McKenzie JE; Cox GR; Simmons MB; Merry SN
    Cochrane Database Syst Rev; 2012 Nov; 11(11):CD004851. PubMed ID: 23152227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Severe withdrawal symptoms with fever during paroxetine tapering off].
    Peeters FP; Zandbergen J
    Ned Tijdschr Geneeskd; 1999 Jul; 143(27):1429-31. PubMed ID: 10422558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Controlled-release paroxetine in the treatment of patients with social anxiety disorder.
    Lepola U; Bergtholdt B; St Lambert J; Davy KL; Ruggiero L
    J Clin Psychiatry; 2004 Feb; 65(2):222-9. PubMed ID: 15003077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Better tolerability of St. John's wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression.
    Kasper S; Gastpar M; Möller HJ; Müller WE; Volz HP; Dienel A; Kieser M
    Int Clin Psychopharmacol; 2010 Jul; 25(4):204-13. PubMed ID: 20568656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of paroxetine for the treatment of depression and anxiety disorders in the elderly: a review.
    Bourin M
    Hum Psychopharmacol; 2003 Apr; 18(3):185-90. PubMed ID: 12672169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands.
    Bakker MK; Kölling P; van den Berg PB; de Walle HE; de Jong van den Berg LT
    Br J Clin Pharmacol; 2008 Apr; 65(4):600-6. PubMed ID: 17953715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study.
    Montgomery SA; Kennedy SH; Burrows GD; Lejoyeux M; Hindmarch I
    Int Clin Psychopharmacol; 2004 Sep; 19(5):271-80. PubMed ID: 15289700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of Dementia Among Elderly Nursing Home Patients Using Paroxetine and Other Selective Serotonin Reuptake Inhibitors.
    Bali V; Chatterjee S; Carnahan RM; Chen H; Johnson ML; Aparasu RR
    Psychiatr Serv; 2015 Dec; 66(12):1333-40. PubMed ID: 26234334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paroxetine-induced somnambulism.
    Kawashima T; Yamada S
    J Clin Psychiatry; 2003 Apr; 64(4):483. PubMed ID: 12716257
    [No Abstract]   [Full Text] [Related]  

  • 38. Dose-response relationship of selective serotonin reuptake inhibitors treatment-emergent hypomania in depressive disorders.
    Ramasubbu R
    Acta Psychiatr Scand; 2001 Sep; 104(3):236-8; discusiion 238-9. PubMed ID: 11531662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder.
    Seedat S; Stein MB
    J Clin Psychiatry; 2004 Feb; 65(2):244-8. PubMed ID: 15003080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Case Report of Serotonin Syndrome in a Patient on Selective Serotonin Reuptake Inhibitor (SSRI) Monotherapy.
    Hudd TR; Blake CS; Rimola-Dejesus Y; Nguyen TT; Zaiken K
    J Pharm Pract; 2020 Apr; 33(2):206-212. PubMed ID: 31030620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.